Postponement of CPHI & PMEC China 2022
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
Due to the sudden and unexpected rise in COVID-19 cases in Shanghai and local cities, we have taken the decision to postpone the in-person CPhI & P-MEC China event from 16-18 December 2021 to 21-23 June 2022.
The Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session in 2021, with the platform functionally optimized for better user experience. The portal for the “Thailand & Indonesia – Natural Extracts Session” is officially launched to welcome the online participation of both natural extracts suppliers in Zhejiang Province of China, as well as buyers from Thailand and Indonesia.
The Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session in 2021, with the platform functionally optimized for better user experience. The portal for the “Australia & New Zealand – APIs Session” is officially launched to welcome the online participation of both fine chemical suppliers in Zhejiang Province of China, as well as buyers from Australia & New Zealand.
The Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session in 2021, with the platform functionally optimized for better user experience. The portal for the “USA & Canada – Fine Chemicals Session” is officially launched to welcome the online participation of both fine chemical suppliers in Zhejiang Province of China, as well as buyers from USA & Canada.
PharmaSources.com, an international B2B trade portal for the pharmaceutical verticals, is launching the virtual event E-Trade Season together with CPhI and P-MEC China from March to June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. This includes months of informative content and targeted matchmaking service – delivering over 8 themed webinar series and showcasing high-quality pharma suppliers from different pharmaceutical sectors.
The Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session in 2021, with the platform functionally optimized for better user experience. The portal for the “Japan & Republic of Korea – Natural Extracts Session” is officially launched to welcome the online participation of both natural extracts suppliers in Zhejiang Province of China, as well as buyers from Japan and Republic of Korea.
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a new session. The portals for the “Middle East – APIs session” is now launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as Middle East buyers online.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session. The portals for the “USA – Natural Extracts session” is officially launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as USA buyers online.
With over 4000 pharmaceutical companies, China is the second-largest pharmaceutical industry globally. A report by Deux Consulting shows that China is estimated to reach $161.8 billion by 2023 and take a 30% share of the global market. The October Pharma Sources Insight will provide insights into the Chinese pharmaceutical industry on the following aspects, which offers an industry landscape in China.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a fresh new session. The portals for the “Germany & France – Natural Extracts session” is officially launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as German and French buyers online.
Virtual Expo Connect to empower access for international pharma to the world’s largest pharma ingredients market
Zhejiang Quality APIs Industry (Shaoxing) Virtual Expo is now launched to welcome the participation of both pharmaceutical suppliers located in Shaoxing of Zhejiang Province of China, and global buyers online.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a new session. The portals for the “Russia – API session” is now launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as Russian buyers online.
Pharma Sources Insight August 2020 focuses on the following topics:
PharmaSources.com, the vertical B2B portal for the pharmaceutical industry, announces the launch of the virtual session CPhI China Top API Exporters & Products on 24-28 August 2020, as part of the CPhI & P-MEC China E-Trade Season (August to October 2020).
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming with a new session. The portals for the “Japan & South Korea – API session” is now launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as Japanese & South Korean buyers online.
PharmaSources, an international B2B trade portal for the pharmaceutical verticals, is launching the virtual event CPhI & P-MEC China E-Trade Season from August to December 2020. Consisting of the three sessions “Top API Exporters & Products”, “Popular Natural Extracts for Health and Pharma” and “P-MEC China Webinar: Russia Pharmaceutical Manufacturing and Machinery”, the E-Trade Season is to facilitate digital sourcing solutions, learning opportunities and business connections for global pharmaceutical practitioners.
Fantastic! The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) is coming back with a new session- the portals for the “Pakistan- API Session” is now launched to create a specific online platform for pharmaceutical suppliers in Zhejiang Province of China as well as Pakistani buyers to precisely target quality business partners.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) has entered into the fourth week. The portals for the “North America – Pharma Machinery”, “India – Pharma Intermediates” and “Europe – Fine Chemicals” have now been launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as European & Indian & North America buyers online.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) has entered into the third week. The portals for the “Europe – Pharma Machinery”, “Europe – Pharma Intermediates” and “India – Fine Chemicals” have now been launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as European & Indian buyers online.
The 2020 Zhejiang Export Commodity Online Fair (Pharma Sector) has ushered in a second week. The portals for the “Europe – APIs” and “North America – APIs” this week have now been launched separately to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as European & North American buyers online.
Zhejiang Province of China has established international trade and business with more than 200 countries and region. Situated along China’s southeast coast by south of Yangtze River Delta, it is China’s leading pharmaceutical manufacturing, R&D and service center, where total pharma output value is expected to exceed 300 billion RMB by 2022.
The global pandemic of COVID-19 has changed the focus towards epidemic prevention and control of the infection in all areas of the world. The WHO is sparing no effort to call all nations to strengthen unity and cooperation to fight the epidemic disease spread. The scientific world has been searching for weeks for a coronavirus vaccine, while continuing investigations on how to treat patients. This global approach has significantly accelerated the development of therapeutic drugs for the treatment of COVID-19 infection, targeting to improve the cure rate and to reduce the death toll as top priority.
Amsterdam, 20 April 2020: CPhI & P-MEC China 2020, the landmark 20th anniversary edition of China’s largest pharma exhibition, will now take place on 16-18 December 2020 at SNIEC in Shanghai [rescheduled from June 22-24, 2020].
New cases of novel coronavirus infection in Wuhan, Central China’s Hubei province, are expected to be zero at the end of this month, Zhang Boli, a member of the work group sent by the central government to guide epidemic control work in Hubei, said recently.
According to the website of the State Council Information Office (SCIO), on 5 March, a SCIO press briefing was held on China’s participation in international cooperation to combat the COVID-19 outbreak.
MUMBAI, March 4 (Xinhua) — China will emerge stronger from the coronavirus challenge, experts said at a seminar here on Tuesday, while lauding China’s efforts to stem the impact of the COVID-19 epidemic.
A key Party meeting on Wednesday presided over by Xi Jinping, general secretary of the Communist Party of China Central Committee, stressed the need to unleash consumer demand that has been restrained during the novel coronavirus pneumonia outbreak and continuing to expand opening-up.
China’s leading medical artificial intelligence startups are helping medical workers on the frontline deal with the novel coronavirus outbreak, using medical imaging devices embedded with AI for clinical diagnosis of the disease.
BEIJING, March 3 (Xinhua) — As China is fighting a tough war against the novel coronavirus disease (COVID-19) outbreak, Chinese President Xi Jinping has underscored international cooperation in scientific research guided by the vision of a community with a shared future for humanity.
The outbreak of novel coronavirus pneumonia in China peaked in late February and will level off in late April, new research headed by respiratory scientist Zhong Nanshan predicted.
This document provides updated recommendations for international traffic in relation to the COVID-19 outbreak, in light of the rapidly evolving situation. It supersedes the advice published on 27 January 2020.
On 2 March, Foreign Ministry spokesperson Zhao Lijian gave a regular press conference. When asked for comment on the tightening prevention and control measures taken by different localities in China against overseas arrivals, Zhao has the following to say:
A total of 125 new confirmed cases of novel coronavirus infection and 31 deaths were reported on Monday on the Chinese mainland, bringing the two numbers up to 80,151 and 2,943 respectively, the National Health Commission said Tuesday morning.
Zhao Jianping (3rd R), a respiratory and critical care specialist from the Wuhan-based Tongji Hospital, instructs his colleagues at the severe case ward in Wuhan, central China’s Hubei Province, Feb. 18, 2020. (Xinhua/Wang Yuguo)
The Chinese government will donate 5,000 sets of protective clothing and 100,000 masks to Japan in batches, the first two of which arrived in Tokyo on February 27 and 28 in order to help Japan to fight against the novel coronavirus, the Chinese Embassy in Japan said in a statement on Saturday.
Maintaining sustainable and healthy economic growth this year is a key objective, and China’s economy remains resilient despite mounting risks and challenges at home and abroad, a senior official said on Friday.
The novel coronavirus epidemic has been easing in China, including in the epicenter city of Wuhan, in Hubei province, but great uncertainties remain and epidemic control efforts must not become lax in any case, the nation’s top health authority said on Feb 28.
At a press conference held by the State Council inter-agency task force on COVID-19 outbreak on the afternoon of 4 March, Mr. Mi Feng, a spokesperson of the National Health Commission and Deputy Director-General for Communications noted that as of 3 March, the cure rates of confirmed cases had been on the rise for the 19th consecutive day, with the figure reaching 50.2% in Wuhan, 76.8% in other parts of Hubei and 87.3% in other provinces. In the coming weeks, it is important to lock in treatment gains, further improve the therapeutic solutions, harness the strengths of both traditional Chinese medicine and western medicine, closely monitor and provide all-round care to patients in severe or critical conditions, so as to further increase the cure rate and lower the case fatality rate.
The novel coronavirus pneumonia epidemic is likely to be brought under control on the Chinese mainland by the end of April, said renowned respiratory expert Zhong Nanshan, who also called for enhanced global cooperation to fight the disease.
1. Between 00:00 and 24:00, 26 February, the following were newly reported by the 31 provinces, autonomous regions and municipalities and the Xinjiang Production and Construction Corps:
China is strengthening preventive measures to monitor incoming visitors as the novel coronavirus epidemic spreads in other countries.
Flexible, targeted monetary policy aims to help businesses survive epidemic
On 25 February, at a press briefing of the State Council inter-agency task force on responding to the novel coronavirus pneumonia outbreak, Director General of the Department of Social Development of the National Development and Reform Commission Ou Xiaoli elaborated on the principle of region-specific, targeted resumption of work and production. Under this principle, each county, with the exception of those in Hubei Province and Beijing Municipality, will be categorized as either low-risk, medium-risk or high-risk in light of its outbreak intensity.
At the press briefing organized by the State Council inter-agency task force on COVID-19 outbreak on the afternoon of 26 February, Mi Feng, an NHC spokesperson, said that between 00:00 and 24:00, 25 February, 406 confirmed cases, 52 fatal cases (all in Hubei province) and 439 suspected cases were newly reported by the 31 provinces, autonomous regions and municipalities and the Xinjiang Production and Construction Corps.
BEIJING — The State Council, China’s cabinet, on Feb 25 unveiled a string of measures to facilitate the employment of college graduates and rural migrant workers, offer financial support to micro-, small- and medium-sized enterprises and solve the difficulties of self-employed persons to reduce the impact of the coronavirus epidemic on the economy.
BEIJING, Feb. 26 (Xinhua) — China has issued a set of new guidelines for judicial and law enforcement institutions on handling legal issues concerning the resumption of production alongside the prevention and control of the COVID-19 epidemic.
China will roll out a set of strong financial policies, including encouraging financial institutions to provisionally defer loan payments and increase lending at concessional rates for micro, small and medium-sized businesses as part of supportive efforts undertaken as they resume operations amid a difficult situation.
Good afternoon everyone.
GENEVA, Feb. 25 (Xinhua) — China has changed the course of COVID-19 outbreak, Bruce Aylward, an epidemiologist who led an advance team from the World Health Organization (WHO), said here on Tuesday, noting a rapidly escalating outbreak in China has plateaued and come down faster than previously expected.
China will facilitate more foreign companies in resuming work and production amid the novel coronavirus epidemic in order to stabilize the global supply chain, a senior official of the Ministry of Commerce said on Monday.
BEIJING — China’s unprecedented public health responses to the COVID-19 outbreak have yielded notable results in blocking human-to-human transmission of the virus, preventing or at least delaying hundreds of thousands of cases, said a joint expert team consisting of experts from China and the World Health Organization.
China will speed up the resumption of delivery services to aid the nation’s epidemic control and prevention efforts and make sure people can get deliveries of daily necessities amid the ongoing novel coronavirus outbreak, a senior transport official said.
BEIJING, Feb. 23 (Xinhua) — Chinese President Xi Jinping on Sunday stressed unremitting efforts in the prevention and control of the novel coronavirus disease (COVID-19) epidemic and coordination in advancing economic and social development.
At the press briefing given by the State Council inter-agency task force on COVID-19 outbreak on the afternoon of 23 February, Mi Feng, an NHC spokesperson, said that between 00:00 and 24:00, 22 February, 18 confirmed cases, 251 suspected cases and 1 fatal case were newly reported outside Hubei and the number of severe cases down by 45. New confirmed cases dropped below five or to zero in all provinces other than Hubei. The number of new confirmed cases outside Hubei dropped from the Peak of 890 to 18 on 22 February, showing a fluctuating downward trend. 16 provinces and the Xinjiang Production and Construction Corps haven’t seen any new confirmed cases for more than two consecutive days.
On the afternoon of 22 February, at the 27th local press briefing on the epidemic control of the novel coronavirus disease (COVID-19) in Zhejiang Province, Song Zhiheng, deputy head of the Science and Technology Department of Zhejiang Province, said that the first batch of vaccines has successfully induced antibody production and entered the stage of animal test. The cultivation of recombinant virus for the development of recombinant adenovirus vector vaccine has started, and animal test will begin soon. In Zhejiang Province, scientists are already conducting vaccine research based on the fourth generation of the coronavirus, and they are now racing against time to seek breakthroughs. Despite these positive developments, it is important to recognize that there is a long R&D cycle for vaccines and the law of science must be respected to make sure that the research process is strictly science-based and safe.
Exporters to get more assistance from govt for resumption of production
Premier Li Keqiang called for more output in medical material in an effort to support epidemic prevention and control and the country’s return to work and production.
BEIJING — President Xi Jinping stressed improving the mechanism for major epidemic prevention and control and the national public health emergency management system.
BRUSSELS, Feb. 21 (Xinhua) — A leading Belgian infectious diseases specialist has praised China for its strong measures to stop the COVID-19 outbreak.
VIENTIANE, Feb. 20 (Xinhua) — Chinese State Councilor and Foreign Minister Wang Yi said here on Thursday that the limited and short-term impact from the novel coronavirus (COVID-19) outbreak will not reverse the growth of China’s economy.
SHANGHAI — Chinese travelers and businesses have expressed confidence in the development of the country’s tourism industry, although it was hit hard by the coronavirus outbreak.
BEIJING — China has stepped up efforts to curb the spread of the novel coronavirus. Here are the latest developments:
BEIJING, Feb. 20 (Xinhua) — Party leaders of more countries have expressed their confidence in China’s defeating the novel coronavirus disease and rapidly restoring its economic growth.
Xi said that China has confidence and capacity to achieve this year’s targets for economic and social development.
Hubei province, center of the novel coronavirus outbreak, reported 349 new confirmed cases of the novel coronavirus, a drop for three consecutive days by the end of Wednesday, according to the province’s health commission.
It notes that highest-level control measures have proved effective in containing outbreak
19.02.2020 21:55 BEIJING — China has released a guideline requiring local authorities to work out differentiated measures for different county-level regions to fight the novel
BEIJING, Feb. 18 (Xinhua) — The daily number of newly confirmed cases of the novel coronavirus disease (COVID-19) reported across China Monday dropped to under 2,000 for the first time, Mi Feng, an official with the National Health Commission, said Tuesday.
The Paper (www.thepaper.cn) learned from the press conference held by the State Council inter-agency task force at 15:00, 18 February that the number of new confirmed cases of the novel coronavirus pneumonia (NCP, or COVID-19) has dropped for 14 consecutive days. On 17 February, compared with the peak, for the first time, the number of daily new confirmed cases nationwide dropped below 2,000. For the first time, the number of daily new confirmed cases outside Hubei went below 100. And for the first time, the number of daily new fatal cases nationwide fell below 100. These three “first times” show that the outbreak is trending further in a positive direction.
China’s new confirmed cases of novel coronavirus pneumonia outside Hubei Province, where the epicenter city of Wuhan is located, has been dropping for 14 consecutive days, according to the National Health Commission. Till 18th Feb, 12563 patients were released from hospitals after being cured in the mainland of China, achieving an overall cure rate of 17.3% (out of 72530 total confirmed cases), compared to the rate of 1.3% on 27 January. The figures show that treatment measures are achieving effective results across the country.
Favilavir, formerly known as Fapilavir, an antiviral that has shown efficacy in treating the novel coronavirus, was approved for marketing, the Taizhou government in Zhejiang province announced Sunday.
On the afternoon of 17 February, the State Council inter-agency task force on responding to the novel coronavirus pneumonia (NCP, or COVID-19) outbreak held a press briefing on the latest progress in medical treatment of NCP cases.
BEIJING, Feb. 18 (Xinhua) — China’s daily new confirmed cases of the novel coronavirus pneumonia outside Hubei, the epicenter province of the outbreak, have dropped for 14 consecutive days, according to the National Health Commission Tuesday.
Here are some encouraging medical research developments achieved over the weekend related to the fight against the novel coronavirus.